Telotristat | LP-778902 | CAS#1033805-28-5 | 1033805-22-9 | 1137608-69-5 | TPH inhibitor

MedKoo Cat#: 319779 | Name: Telotristat

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Telotristat, also known as LP-778902, is the acid form of Telotristat ethyl, and the active metabolite of LX1606 (Telotristat etiprate), which is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor and serotonin synthesis inhibitor with potential antiserotonergic activity. Blocking peripheral serotonin synthesis by telotristat reduces severity of both chemical- and infection-induced intestinal inflammation.

Chemical Structure

Telotristat

CAS#1033805-28-5 (acid)

Theoretical Analysis

MedKoo Cat#: 319779

Name: Telotristat

CAS#: 1033805-28-5 (acid)

Chemical Formula: C25H22ClF3N6O3

Exact Mass: 546.1394

Molecular Weight: 546.94

Elemental Analysis: C, 54.90; H, 4.05; Cl, 6.48; F, 10.42; N, 15.37; O, 8.78

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 400.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1137608-69-5 (etiprate) 1033805-22-9 (ethyl) 1033805-28-5 (acid) 1374745-52-4 (besilate)

Synonym

LP-778902; LP 778902; LP778902; Telotristat

IUPAC/Chemical Name

(S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid

InChi Key

NCLGDOBQAWBXRA-PGRDOPGGSA-N

InChi Code

InChI=1S/C25H22ClF3N6O3/c1-13-8-9-35(34-13)20-11-16(26)6-7-17(20)22(25(27,28)29)38-21-12-19(32-24(31)33-21)15-4-2-14(3-5-15)10-18(30)23(36)37/h2-9,11-12,18,22H,10,30H2,1H3,(H,36,37)(H2,31,32,33)/t18-,22+/m0/s1

SMILES Code

O=C(O)[C@@H](N)CC1=CC=C(C2=NC(N)=NC(O[C@H](C3=CC=C(Cl)C=C3N4N=C(C)C=C4)C(F)(F)F)=C2)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# CAS#1033805-22-9 (Telotristat ethyl) CAS#1033805-28-5 (Telotristat) CAS#1137608-69-5 (Telotristat etiprate)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 546.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Margolis KG, Stevanovic K, Li Z, Yang QM, Oravecz T, Zambrowicz B, Jhaver KG, Diacou A, Gershon MD. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut. 2014 Jun;63(6):928-37. doi: 10.1136/gutjnl-2013-304901. Epub 2013 Jun 7. PMID: 23749550; PMCID: PMC4034681. 2: Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct;21(5):705-14. doi: 10.1530/ERC-14-0173. Epub 2014 Jul 10. PMID: 25012985; PMCID: PMC4295770. 3: Pavel M, Hörsch D, Caplin M, Ramage J, Seufferlein T, Valle J, Banks P, Lapuerta P, Sands A, Zambrowicz B, Fleming D, Wiedenmann B. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015 Apr;100(4):1511-9. doi: 10.1210/jc.2014-2247. Epub 2015 Jan 30. PMID: 25636046. 4: Kim JJ, Wang H, Terc JD, Zambrowicz B, Yang QM, Khan WI. Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2015 Sep 15;309(6):G455-65. doi: 10.1152/ajpgi.00299.2014. Epub 2015 Jul 23. PMID: 26206858. 5: Brommage R, Liu J, Doree D, Yu W, Powell DR, Melissa Yang Q. Adult Tph2 knockout mice without brain serotonin have moderately elevated spine trabecular bone but moderately low cortical bone thickness. Bonekey Rep. 2015 Jul 15;4:718. doi: 10.1038/bonekey.2015.87. PMID: 26229596; PMCID: PMC4516133. 6: Boutzios G, Kaltsas G. Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms. Front Horm Res. 2015;44:40-57. doi: 10.1159/000382053. Epub 2015 Aug 14. PMID: 26303703. 7: Sbardella E, Grossman A. New Developments in the Treatment of Neuroendocrine Tumours - RADIANT-4, NETTER-1 and Telotristat Etiprate. Eur Endocrinol. 2016 Mar;12(1):44-46. doi: 10.17925/EE.2016.12.01.44. Epub 2016 Mar 15. PMID: 29632589; PMCID: PMC5813460. 8: Gelhorn HL, Kulke MH, O'Dorisio T, Yang QM, Jackson J, Jackson S, Boehm KA, Law L, Kostelec J, Auguste P, Lapuerta P. Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach. Clin Ther. 2016 Apr;38(4):759-68. doi: 10.1016/j.clinthera.2016.03.002. Epub 2016 Mar 31. PMID: 27041406; PMCID: PMC9047308. 9: Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors. Oncologist. 2016 Jun;21(6):701-7. doi: 10.1634/theoncologist.2015-0455. Epub 2016 Apr 22. PMID: 27107003; PMCID: PMC4912367. 10: Cives M, Soares HP, Strosberg J. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol. 2016 Jul;28(4):359-66. doi: 10.1097/CCO.0000000000000299. PMID: 27138571. 11: Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R, Mete O, Pasieka J, Rivera J, Wong R, Segelov E, Rayson D. Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence- based Canadian consensus. Cancer Treat Rev. 2016 Jun;47:32-45. doi: 10.1016/j.ctrv.2016.05.003. Epub 2016 May 17. PMID: 27236421. 12: Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol. 2016 May;3(2):175-189. doi: 10.2217/ije-2015-0004. Epub 2016 Apr 8. PMID: 27347369; PMCID: PMC4915384. 13: Welford RW, Vercauteren M, Trébaul A, Cattaneo C, Eckert D, Garzotti M, Sieber P, Segrestaa J, Studer R, Groenen PM, Nayler O. Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation. Sci Rep. 2016 Jul 21;6:30059. doi: 10.1038/srep30059. PMID: 27444653; PMCID: PMC4956766. 14: Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016 Nov;17(16):2191-2205. doi: 10.1080/14656566.2016.1236916. Epub 2016 Sep 23. PMID: 27635672; PMCID: PMC5545682. 15: Lamarca A, Barriuso J, McNamara MG, Hubner RA, Valle JW. Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opin Pharmacother. 2016 Dec;17(18):2487-2498. doi: 10.1080/14656566.2016.1254191. Epub 2016 Nov 16. PMID: 27817224. 16: Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017 Jan;35(1):14-23. doi: 10.1200/JCO.2016.69.2780. Epub 2016 Oct 28. PMID: 27918724. 17: Baker DE, Demaris K. Defibrotide. Hosp Pharm. 2016 Nov;51(10):847-854. doi: 10.1310/hpj5110-847. PMID: 27928191; PMCID: PMC5135434. 18: Cives M, Strosberg J. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. Curr Treat Options Oncol. 2017 Mar;18(3):14. doi: 10.1007/s11864-017-0461-5. PMID: 28286921. 19: Markham A. Telotristat Ethyl: First Global Approval. Drugs. 2017 May;77(7):793-798. doi: 10.1007/s40265-017-0737-x. PMID: 28382568. 20: Choy M. Pharmaceutical Approval Update. P T. 2017 May;42(5):304-305. PMID: 28479837; PMCID: PMC5398621.